Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.3652W HIGH $14.06
Volume
1.15 M
Value Traded
19.34 M
Short % Float
20.3%
+7.58%Week
+19.89%1 Month
-15.4%3 Month
-14.45%6 Month
-85.68%5 Year
-28.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
349.17 M
EPS (TTM)
-3.45
P/E Ratio
-
Ent. Value
799.17 M
Total Shares
51.27 M
Float Shares
48.20 M
Insiders
6.00%
Institutions
88.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EBS Catalyst Timeline
Dated clinical, regulatory and corporate events for Emergent BioSolutions Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Emergent BioSolutions Inc.
817Total events
7Upcoming
249Tier-1 (high impact)
2014 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Ribbon cutting ceremony marking manufacturing restart and growth of Canton, MA facility
▲Partnership / LicenseCYFENDUSApprovedCorporate
BARDA contract modification valued at approximately $24 million to supply CYFENDUS
anthrax preparednesssource ↗
▲Other Regulator MilestoneCYFENDUSApprovedEx-US Regulatory
BARDA contract modification valued at approximately $24 million to supply CYFENDUS
anthrax preparednesssource ↗
▲Other Regulator MilestoneEx-US Regulatory
Government of Canada standing offer awarded for NARCAN Nasal Spray
opioid overdosesource ↗
▲Product LaunchPost-Market
Government of Canada standing offer awarded for NARCAN Nasal Spray
opioid overdosesource ↗
▲Partnership / LicenseSAB-142Corporate
Secured strategic manufacturing partnership with SAB Biotherapeutics for SAB-142
type 1 diabetessource ↗
▲Partnership / LicenseCorporate
Secured manufacturing partnership with Substipharm Biologics for Japanese Encephalitis vaccine
Japanese Encephalitissource ↗
▲FDA ApprovalACAM2000ApprovedFDA Decision
Received approval from Singapore Health Sciences Authority for expanded indication of ACAM2000 to include mpox
mpoxsource ↗
▲FDA ApprovalFDA Decision
Announced launch of new NARCAN Nasal Spray Carrying Case and multipack configurations following FDA approvals on supplemental new drug applications
opioid overdosesource ↗
▼Restructuring LayoffsCorporate
Restructuring business operations with reduction of approximately 90 roles
●Management ChangeCorporate
Stephanie Duatschek to assume role of Executive Vice President, Chief Growth Officer
●Debt Royalty FinancingCorporate
Refinanced term loan with new $150 million facility and amended asset-backed loan facility
▲Partnership / LicenseCorporate
Announced partnership with British Columbia to supply NARCAN Nasal Spray for expanded Take Home Naloxone Program
opioid overdosesource ↗
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Received approval from Singapore Health Sciences Authority for expanded indication of ACAM2000 to include mpox
mpoxsource ↗
▲Other Regulator MilestoneBAT®Ex-US Regulatory
Executed $64.5 million for BAT contract modification with U.S. government
botulismsource ↗
▲Supplemental ApprovalFDA Decision
Received FDA approvals on supplemental new drug applications for NARCAN Nasal Spray carrying case and multipack configurations
opioid overdosesource ↗
●PublicationCYFENDUSApprovedPresentation
NEJM Evidence study on CYFENDUS for post-exposure prophylaxis after anthrax exposures in Wyoming
anthrax post-exposure prophylaxissource ↗
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approved expanded indication for ACAM2000 to include prevention of mpox disease in high-risk adults
mpoxsource ↗
▲Supply DisruptionACAM2000ApprovedCMC / Inspection
Contract modification valued at $52.7 million from ASPR to supply ACAM2000 vaccine, ancillaries, and diluent replacement lots
smallpox and mpoxsource ↗
▲Partnership / LicenseBAT®Corporate
Emergent receives $64.5 million contract modification from ASPR for BAT®
symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or Gsource ↗
◆Oral PresentationPresentation
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference
◆Oral PresentationPresentation
Goldman Sachs 11th Annual Leveraged Finance and Credit Conference
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approval for expanded indication to include mpox
mpoxsource ↗
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approved expanded indication for ACAM2000 to include mpox
mpoxsource ↗
▲Partnership / LicenseSAB-142Corporate
Secured strategic manufacturing partnership with SAB Biotherapeutics for SAB-142
type 1 diabetessource ↗
▲Partnership / LicenseCorporate
Secured strategic manufacturing partnership with Substipharm Biologics for Japanese Encephalitis vaccine
Japanese Encephalitissource ↗
▲FDA ApprovalFDA Decision
FDA approvals on supplemental new drug applications for NARCAN Nasal Spray Carrying Case and Multipacks
opioid overdosesource ↗
▲FDA ApprovalACAM2000ApprovedFDA Decision
Singapore Health Sciences Authority approved expanded indication of ACAM2000 to include mpox
mpoxsource ↗
▲Debt Royalty FinancingCorporate
Refinanced term loan with new $150M facility and amended asset-backed loan facility
▲Partnership / LicenseCorporate
Announced partnership with British Columbia to supply NARCAN Nasal Spray for expanded BC Take Home Naloxone Program
opioid overdosesource ↗
▲Other Regulator MilestoneEx-US Regulatory
Secured over $60M new contract award with U.S. Government and new orders with international government partner for smallpox medical countermeasures
▲Other Regulator MilestoneBioThraxApprovedEx-US Regulatory
Secured delivery order up to $21.5M to supply BioThrax to U.S. Department of War in 2026
anthraxsource ↗
▲IP Litigation RulingIP / Competition
Announced resolution of New York Attorney General investigation related to legacy claims
▲Product LaunchPost-Market
Launched new NARCAN Nasal Spray Carrying Case and Multipacks
opioid overdosesource ↗
▲Partnership / LicenseSAB-142Corporate
Multi-year manufacturing agreement with SAB Biotherapeutics for SAB-142
autoimmune type 1 diabetessource ↗
▲Partnership / LicenseIMOJEVCorporate
Emergent and Substipharm announce strategic manufacturing partnership for IMOJEV
Japanese Encephalitissource ↗
▲Partnership / LicenseNARCANApprovedCorporate
Partnership with British Columbia to supply NARCAN Nasal Spray for expanded BC Take Home Naloxone Program
opioid overdosesource ↗
▲Product LaunchPost-Market
Expanded availability of NARCAN Nasal Spray multipacks (6-count and 24-count)
opioid overdosesource ↗
●Oral PresentationPresentation
College campus engagement at SMU with Emmitt Smith and Zac Clark
opioid overdosesource ↗
▲Partnership / LicenseCorporate
Multi-year agreements with Government of Canada valued up to $140M CAD
biologic threat preparednesssource ↗
▲Other Regulator MilestoneCNJ-016Ex-US Regulatory
ASPR exercises option for additional VIGIV doses under existing contract
smallpox preparednesssource ↗
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
International government partner orders ACAM2000 valued at $6.6M
smallpox biodefensesource ↗
Past FDA Catalysts and PDUFA Decisions
How EBS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-03-29 | Narcan (naloxone hydrochloride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$512M
Pipeline Value
$1.8B
Commercial Value
Undervalued
Valuation Signal
15
Drugs Scored
4.8x
rNPV / MCap
Top 23%
Micro Cap(rank 152 of 658)
Percentile Rank
Emergent BioSolutions Inc. carries a moderate pipeline score (47/100), with $1.3B risk-adjusted pipeline value, led by FLU-IGIV in Influenza A H3N2 (Phase 2), across $168B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $770.2M x 2.3 = $1.8B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Smallpox MCM | $285M | $356M | -20% |
| Naloxone | $209M | $273M | -23.6% |
| Anthrax MCM | $89M | $103M | -14.2% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FLU-IGIV Monoclonal antibodyCompletedNCT03315104 | Influenza A H3N2 | Phase 2 | COMPLETED | 65 | Jun 17, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every EBS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COVID-HIG | COVID-19 | Phase 3 | 2021-04-02 | the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo.Read More | Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DeGolyer Donald WDirector | Sell | -17,800 111,921 held | $7.09 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EBS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.7 % (-22.2 %) | 3.85 M | 459.95 K | -28.03% ( -179.17 K) |
EBS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EBS ranks across every disease it competes in
Competitive Position is a premium feature
See how EBS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEBS News
EBSMedia Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
Emergent BioSolutions will host a ribbon cutting ceremony on September 16, 2026, to celebrate the restart of its Canton manufacturing facility. The event underscores the company's investment in advanced biopharmaceutical manufacturing and aims to bolster domestic capabilities and public health preparedness. Approximately 50 new jobs will be created as part of this initiative.
Read more →EBSEmergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
Emergent BioSolutions has completed a $75 million repurchase of its Senior Unsecured Notes, reducing the outstanding balance to about $364.7 million. This strategic move reflects the company's commitment to strengthening its financial profile while maintaining flexibility for growth. Management plans to discuss this milestone and ongoing transformation efforts at upcoming investor conferences.
Read more →EBSEmergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions has announced a $24 million contract modification from BARDA to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness. This contract underscores the importance of readiness against anthrax threats, particularly in light of its potential use in bioterrorism. CYFENDUS® was FDA-approved in July 2023 for post-exposure prophylaxis in adults aged 18 to 65.
Read more →EBSEmergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
Emergent BioSolutions has secured a standing offer from the Government of Canada to supply NARCAN® Nasal Spray, effective from October 1, 2026, to September 30, 2029. This agreement allows various public sector organizations across Canada to procure the nasal spray, which is crucial for opioid overdose response. The initiative aims to enhance access to this lifesaving treatment amid ongoing public health challenges related to opioid use.
Read more →EBSEmergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
Emergent BioSolutions is reaffirming its commitment to opioid overdose education on International Overdose Awareness Day. The company is expanding its Ready to Rescue campaign, collaborating with Zac Clark to raise awareness on college campuses and partnering with Davis Schneider to address the opioid crisis in Canada. The campaign emphasizes the importance of carrying NARCAN® Nasal Spray to respond effectively to overdose emergencies.
Read more →EBS▼ -29.6%on this news· ran to -41% by day 3
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Emergent BioSolutions reported a 66% increase in total revenues for Q2 2026, reaching $234.3 million, primarily driven by government contract modifications. However, the company faced a significant net loss of $180.2 million, largely due to a non-cash impairment charge. Adjusted net income showed improvement, and the company is restructuring operations to align with current needs, aiming for annual savings of approximately $40 million.
Read more →EBS▼ -29.6%on this news· ran to -41% by day 3
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
Emergent BioSolutions has highlighted the critical need for biological threat preparedness amid evolving global security challenges, including geopolitical conflicts and advancements in AI. The company emphasizes collaboration among government, industry, and academia to enhance national resilience against potential biological incidents. Recent events, including allegations of biological warfare, underscore the urgency of this initiative.
Read more →EBSEmergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
Emergent BioSolutions Inc. will host a conference call on August 5, 2026, to discuss its financial results for the second quarter of 2026. Participants can join via webcast or telephone after registering in advance. The company emphasizes its mission to protect public health through various life-saving solutions.
Read more →EBSEmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions has announced a contract modification worth $52.7 million from the U.S. government for its ACAM2000® vaccine, aimed at smallpox and mpox preparedness. Deliveries are set to begin shortly, reflecting ongoing government efforts in biodefense. The contract follows recent approvals of ACAM2000® in Saudi Arabia and Singapore for high-risk individuals.
Read more →EBS▲ +6.4%on this news
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions is collaborating with Victoria's Voice Foundation to observe National Naloxone Awareness Day on June 6th, aiming to combat the opioid epidemic. Their campaign promotes naloxone accessibility and education through various initiatives, including distributing NARCAN® Nasal Spray. The event honors those lost to overdoses, especially Victoria Siegel, and emphasizes the importance of community preparedness. Future programs include outreach to colleges to further spread awareness and resources related to opioid overdose interventions.
Read more →EBSEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions has received a $64.5 million contract modification from the ASPR to supply its Botulism Antitoxin Heptavalent (BAT®). This modification extends an existing contract and underscores the company's commitment to U.S. biodefense. The BAT® is crucial for treating symptomatic botulism in both adults and children following exposure to botulinum neurotoxin.
Read more →EBSEmergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions Inc. will participate in several upcoming investor conferences, including the Goldman Sachs 11th Annual Leveraged Finance and Credit Conference and the Jefferies Global Healthcare Conference. These events will provide opportunities for the company's senior management to engage with investors and discuss their mission to protect public health. The presentations will be available via webcast.
Read more →EBSEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Emergent BioSolutions has received approval from the Saudi Food and Drug Authority for its ACAM2000® vaccine, which is designed to prevent smallpox and mpox in high-risk individuals. This marks the first product from Emergent to be licensed by the SFDA. The approval follows a similar recent endorsement from Singapore's Health Sciences Authority. The vaccine addresses a critical public health threat amid rising global cases of mpox.
Read more →EBSEmergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions Inc. reported its financial results for Q1 2026, with total revenues of $156.1 million, a decrease of 30% compared to the same period in 2025. The net income dropped significantly by 90% to $6.8 million, reflecting challenges in product sales, particularly in the Anthrax and Smallpox segments. However, the company highlighted the establishment of a strategic manufacturing partnership and efforts to maintain its market share in the NARCAN product line. Additionally, Emergent is working on refinancing its debt to enhance financial flexibility amidst ongoing operational transformations.
Read more →EBSEmergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
Emergent BioSolutions has received approval from Singapore's Health Sciences Authority for an expanded indication of ACAM2000®, allowing its use for the prevention of mpox in high-risk adults. This decision is supported by safety data and an effective animal study. The approval aims to enhance public health preparedness during mpox outbreaks.
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Emergent BioSolutions Inc. (EBS) reported a total revenue of $156.1 million and a net income of $6.8 million for Q1 2026, reflecting a significant decline compared to the same quarter in 2025. The company experienced a 30% decrease in total revenues and a 90% drop in net income year-over-year. Despite these challenges, Emergent secured strategic manufacturing partnerships and maintained its market position with NARCAN Nasal Spray. The company is also progressing with a multi-year transformation plan aimed at enhancing its operational efficiency and financial stability.
Read more →EBSEmergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
Emergent BioSolutions has partnered with baseball player Davis Schneider to raise awareness about NARCAN® Nasal Spray in Canada. Schneider shares his family's experience with opioid overdose to highlight the importance of being prepared. The initiative aims to combat the opioid crisis, which has claimed over 53,000 lives in Canada since 2016. NARCAN® can reverse opioid overdoses and is available at no cost in several provinces.
Read more →EBSEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Emergent BioSolutions has entered a multi-year contract with SAB Biotherapeutics valued at approximately $50 million to support the development and manufacturing of SAB-142, a candidate for Type 1 Diabetes. The agreement includes end-to-end services compliant with good manufacturing practices and highlights the capabilities of Emergent's Winnipeg facility. This partnership aims to enhance the production of SAB-142 as it progresses through clinical trials.
Read more →EBSEmergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent BioSolutions has entered a $34.5 million partnership with Substipharm Biologics to manufacture the Japanese Encephalitis vaccine, IMOJEV®, at its Canton facility. Emergent will also serve as the exclusive distributor of the vaccine to the U.S. government, pending FDA approval. This partnership aims to bolster U.S. preparedness against JE and enhance the vaccine's availability in the market.
Read more →About Emergent BioSolutions Inc.
Headquarters300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
BIOPHARMAWATCH ELITE PLUS
Trade the next EBS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime